Axa S.A. Acquires 62,784 Shares of Enovis Co. (NYSE:ENOV)

AXA S.A. boosted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 208.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 92,909 shares of the company's stock after acquiring an additional 62,784 shares during the quarter. AXA S.A. owned approximately 0.16% of Enovis worth $4,077,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC raised its position in shares of Enovis by 16.1% during the third quarter. Barclays PLC now owns 368,488 shares of the company's stock worth $15,864,000 after acquiring an additional 51,151 shares during the last quarter. Retirement Systems of Alabama increased its position in Enovis by 10.1% in the third quarter. Retirement Systems of Alabama now owns 67,846 shares of the company's stock worth $2,921,000 after purchasing an additional 6,239 shares during the period. Fiduciary Financial Group LLC acquired a new position in Enovis during the 4th quarter valued at about $268,000. Oak Thistle LLC acquired a new position in Enovis during the 4th quarter valued at about $324,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of Enovis in the 4th quarter valued at about $437,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ENOV. Needham & Company LLC dropped their price target on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday. JMP Securities dropped their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday.

Enovis Trading Up 1.5%

ENOV traded up $0.55 during midday trading on Tuesday, reaching $37.12. 151,961 shares of the company were exchanged, compared to its average volume of 769,736. The stock has a market capitalization of $2.12 billion, a P/E ratio of -16.95 and a beta of 1.79. Enovis Co. has a one year low of $29.32 and a one year high of $53.84. The stock's 50-day simple moving average is $35.18 and its 200 day simple moving average is $41.55. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. The business had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis's quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 EPS. As a group, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.